These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1046 related items for PubMed ID: 32575795

  • 1. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ, Hsu SM, Chien CY, Wang YH, Hsu MH, Suk FM.
    Molecules; 2020 Jun 20; 25(12):. PubMed ID: 32575795
    [Abstract] [Full Text] [Related]

  • 2. Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma.
    Suk FM, Liu CL, Hsu MH, Chuang YT, Wang JP, Liao YJ.
    Sci Rep; 2019 Nov 21; 9(1):17259. PubMed ID: 31754201
    [Abstract] [Full Text] [Related]

  • 3. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 4. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W, Xu B, Li Q, Jiang D, Yan S.
    Mol Med Rep; 2018 Apr 08; 17(4):6185-6193. PubMed ID: 29484394
    [Abstract] [Full Text] [Related]

  • 5. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May 08; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

  • 6. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y.
    Biomed Pharmacother; 2019 Jun 08; 114():108864. PubMed ID: 30981107
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, Ngan ES, Lo CM, Man K, Ding J, Lee TK, Ma S.
    J Hepatol; 2018 Oct 08; 69(4):826-839. PubMed ID: 29885413
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Polyphyllin I attenuates the invasion and metastasis via downregulating GRP78 in drug-resistant hepatocellular carcinoma cells.
    Du H, Wu H, Kang Q, Liao M, Qin M, Chen N, Huang H, Huang D, Wang P, Tong G.
    Aging (Albany NY); 2023 Nov 06; 15(21):12251-12263. PubMed ID: 37934581
    [Abstract] [Full Text] [Related]

  • 10. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J, Liu Y, Meng L, Ji B, Yang D.
    Int J Med Sci; 2017 Nov 06; 14(6):523-529. PubMed ID: 28638267
    [Abstract] [Full Text] [Related]

  • 11. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G, Shi Z, Shangguan C, Zhang J, Yuan Y, Chen L, Liu W, Li B, Meng S, Xiong W, Mi J.
    Theranostics; 2021 Nov 06; 11(12):6006-6018. PubMed ID: 33897895
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.
    Int J Cancer; 2012 Aug 01; 131(3):548-57. PubMed ID: 21858812
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 Aug 01; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 16. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
    Yu CC, Huang SY, Chang SF, Liao KF, Chiu SC.
    Molecules; 2020 May 25; 25(10):. PubMed ID: 32466169
    [Abstract] [Full Text] [Related]

  • 17. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L, Zhan Y, Wu Z, Lin M, Jin X, Jiang L, Qiu Y.
    Biomed Pharmacother; 2020 May 25; 125():110033. PubMed ID: 32187962
    [Abstract] [Full Text] [Related]

  • 18. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L.
    J Exp Clin Cancer Res; 2019 May 31; 38(1):232. PubMed ID: 31151472
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL-6/STAT3 pathway.
    Wang W, Lin H, Liu D, Wang T, Zhu Z, Yu P, Zhang J.
    Cancer Sci; 2024 Sep 31; 115(9):2923-2930. PubMed ID: 39014520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.